Purpose: Surgical cytoreduction remains a cornerstone in the management of patients with advanced and recurrent epithelial ovarian cancer. Parenchymal liver metastases determine stage VI disease and are commonly considered a major limit in the achievement of an optimal cytoreduction. The purpose of this manuscript was to discuss the rationale of liver resection and the morbidity related to this procedure in advanced and recurrent ovarian cancer. Methods: A search of the National Library of Medicine’s MEDLINE/PubMed database until March 2015 was performed using the keywords: “ovarian cancer,” “hepatic,” “liver,” and “metastases.” Results: In patients with liver metastases, hepatic resection is associated with a similar prognosis as stage IIIC patients. The length of the disease-free interval between primary diagnosis and occurrence of liver metastases, as well as residual disease after resection, is the most important prognostic factors. In addition, the number of liver lesions, resection margins, and the gynecologic oncology group performance status seem to play also an important role in determining outcome. Conclusions: In properly selected patients, liver resections at the time of cytoreduction increase rates of optimal cytoreduction and improve survival in advanced-stage and recurrent ovarian cancer patients.

Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer / Gasparri, M. L.; Grandi, G.; Bolla, D.; Gloor, B.; Imboden, S.; Panici, P. B.; Mueller, M. D.; Papadia, A.. - In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. - ISSN 0171-5216. - 142:7(2016), pp. 1509-1520. [10.1007/s00432-015-2090-3]

Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer

Grandi G.;
2016

Abstract

Purpose: Surgical cytoreduction remains a cornerstone in the management of patients with advanced and recurrent epithelial ovarian cancer. Parenchymal liver metastases determine stage VI disease and are commonly considered a major limit in the achievement of an optimal cytoreduction. The purpose of this manuscript was to discuss the rationale of liver resection and the morbidity related to this procedure in advanced and recurrent ovarian cancer. Methods: A search of the National Library of Medicine’s MEDLINE/PubMed database until March 2015 was performed using the keywords: “ovarian cancer,” “hepatic,” “liver,” and “metastases.” Results: In patients with liver metastases, hepatic resection is associated with a similar prognosis as stage IIIC patients. The length of the disease-free interval between primary diagnosis and occurrence of liver metastases, as well as residual disease after resection, is the most important prognostic factors. In addition, the number of liver lesions, resection margins, and the gynecologic oncology group performance status seem to play also an important role in determining outcome. Conclusions: In properly selected patients, liver resections at the time of cytoreduction increase rates of optimal cytoreduction and improve survival in advanced-stage and recurrent ovarian cancer patients.
2016
142
7
1509
1520
Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer / Gasparri, M. L.; Grandi, G.; Bolla, D.; Gloor, B.; Imboden, S.; Panici, P. B.; Mueller, M. D.; Papadia, A.. - In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. - ISSN 0171-5216. - 142:7(2016), pp. 1509-1520. [10.1007/s00432-015-2090-3]
Gasparri, M. L.; Grandi, G.; Bolla, D.; Gloor, B.; Imboden, S.; Panici, P. B.; Mueller, M. D.; Papadia, A.
File in questo prodotto:
File Dimensione Formato  
Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer..pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 463.87 kB
Formato Adobe PDF
463.87 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1266649
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 15
social impact